BioPharmSignal logoBioPharmSignal

Biotech News

Novan Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Novan (NOVN)NovanEarnings

- Rhofade prescriptions increased 37% for third quarter year-to-date from prior year -

- Continued progress toward submission of berdazimer gel, 10.3% (SB206) New Drug Application (NDA), targeted around the end of 2022 -

- Company to host conference call today at 8:30 a.m. ET...

Related news

NOVNNovan2021-11-10 05:55 EST

Novan Provides Corporate Update and Reports Third Quarter 2021 Financial Results

NOVNNovan2023-05-15 06:45 EST

Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update

View all latest news

Novan

Novan was a dermatology-focused biotechnology company built around nitric oxide-based therapies for skin conditions and related inflammatory indications. Its story was centered on a narrow clinical platform and the challenge of turning topical science into a durable commercial path.

Recent company news

NOVNNovan2023-07-17 08:45 EST

Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection

NOVNNovan2023-06-05 09:00 EST

Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders

NOVNNovan2023-05-31 16:05 EST

Novan Focuses Strategic Direction and Announces Restructuring

NOVNNovan2023-05-15 06:45 EST

Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update

NOVNNovan2023-05-08 09:05 EST

Novan to Report First Quarter 2023 Financial Results on May 15, 2023

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States